Rakuten Medical Japan Announces Marketing Approval of Akalux(R) IV Infusion 250mg and BioBlade(R) Laser System from the Ministry of Labour, Health and Welfare in Japan for Locoregional Cancer Treatment
SAN MATEO, Calif., Sept. 25, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical Inc. is proud to announce that its wholly owned subsidiary Rakuten Medical Japan K.K. has received marketing approval in Japan from the Ministry of Health, Labo... Biopharmaceuticals, Oncology, Regulatory Rakuten Medical, Akalux, cetuximab saratolacan, BioBlade Laser, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 25, 2020 Category: Pharmaceuticals Source Type: news
Oncotarget: Paradox breaker BRAF inhibitors in BRAF mutant colorectal cancer
(Impact Journals LLC) Oncotarget Volume 11, Issue 34 features Figure 1, " BRAF inhibitor-induced changes in cell viability, " by Pickles, et which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 25, 2020 Category: Cancer & Oncology Source Type: news
Updated BEACON: Doublet as Good as Triplet in Metastatic CRC Updated BEACON: Doublet as Good as Triplet in Metastatic CRC
The combination of encorafenib and cetuximab is just as effective as the triplet with binimetinib in improving survival and is now the standard of care, say experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 2, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
SU2C hails FDA approval Of Encorafenib + Cetuximab for BRAF V600e-Mutant Metastatic CRC
(Stand Up To Cancer) SU2C welcomed the FDA approval of encorafenib+cetuximab combination for patients with advanced BRAF-mutated CRC. In a Phase 1b/2 clinical trial comparing combinations of encorafenib+cetuximab; and encorafenib+alpelisib+cetuximab in BRAF-mutated CRC, observation by the SU2C-KWF Research Team that patients carrying key mutations in genes associated with the MAP kinase signaling pathway were more responsive supported Breakthrough Therapy Designations for both combination, including encorafenib+cetuximab, for patients with BRAF V600E-mutant metastatic colorectal cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2020 Category: Cancer & Oncology Source Type: news
FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutation
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Encorafenib Plus Cetuximab for Metastatic CRC with BRAF V600E Mutation
The FDA approved the combination use of encorafenib and cetuximab for the treatment of adult patients with  BRAFV600E-positive metastatic colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
FDA Approves Braftovi (encorafenib) in Combination with Cetuximab for the Treatment of BRAFV600E-Mutant Metastatic Colorectal Cancer (CRC) After Prior Therapy
April 8, 2020 - Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved Braftovi® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) for the treatment of adult patients with... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 8, 2020 Category: Drugs & Pharmacology Source Type: news
Adding Cetuximab to Chemo Curbs Survival in Resectable Colorectal Liver Metastasis Adding Cetuximab to Chemo Curbs Survival in Resectable Colorectal Liver Metastasis
The combination of chemotherapy and the epidermal-growth-factor receptor (EGFR) antibody cetuximab shortens survival compared with chemotherapy alone in certain patients with colorectal cancer, according to an open-label randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 18, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Cetuximab + chemotherapy in metastatic CRC: not cost effective in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - January 31, 2020 Category: Drugs & Pharmacology Source Type: news
FDA Grants Priority Review to the sNDA for Encorafenib in Combination with Cetuximab
The combination of encorafenib and cetuximab has shown promise in clinical testing for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Triplet Tx Ups Survival in BRAF V600E - Mutated Colorectal Cancer
Overall survival longer for encorafenib, cetuximab, and binimetinib combo versus standard therapy (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - October 4, 2019 Category: Cancer & Oncology Tags: Gastroenterology, Oncology, Pharmacy, Conference News, Source Type: news
Triplet Tx Ups Survival in BRAF V600E-Mutated Colorectal Cancer
FRIDAY, Oct. 4, 2019 -- A triplet combination of therapies (encorafenib, cetuximab, and binimetinib) results in significantly longer overall survival and a higher response rate than standard therapy in patients with metastatic colorectal cancer with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2019 Category: Pharmaceuticals Source Type: news
A systems mechanism for KRAS mutant allele-specific responses to targeted therapy
Cancer treatment decisions are increasingly guided by which specific genes are mutated within each patient’s tumor. For example, agents inhibiting the epidermal growth factor receptor (EGFR) benefit many colorectal cancer (CRC) patients, with the general exception of those whose tumor includes a KRAS mutation. However, among the various KRAS mutations, that which encodes the G13D mutant protein (KRASG13D) behaves differently; for unknown reasons, KRASG13D CRC patients benefit from the EGFR-blocking antibody cetuximab. Controversy surrounds this observation, because it contradicts the well-established mechanisms of EG...
Source: Signal Transduction Knowledge Environment - September 23, 2019 Category: Science Authors: McFall, T., Diedrich, J. K., Mengistu, M., Littlechild, S. L., Paskvan, K. V., Sisk-Hackworth, L., Moresco, J. J., Shaw, A. S., Stites, E. C. Tags: STKE Research Articles Source Type: news
UCLA oncologist Dennis Slamon wins 2019 Lasker Award for clinical medical research
Physician-scientist Dr. Dennis Slamon, professor and chief of hematology/oncology at the David Geffen School of Medicine at UCLA, has been awarded the 2019 Lasker-DeBakey Clinical Medical Research Award for the groundbreaking development of breast cancer drug Herceptin (trastuzumab), a lifesaving therapy for women with HER2-positive breast cancer. He shares the award with H. Michael Shepard, an American cancer researcher honored for work he completed at biotechnology company Genentech; and Axel Ullrich, a German cancer researcher from the Max Planck Institute of Biochemistry.The Albert and Mary Lasker Foundation honored Sl...
Source: UCLA Newsroom: Health Sciences - September 10, 2019 Category: Universities & Medical Training Source Type: news
Oral antibiotic use linked to heightened bowel cancer risk
But lower rectal cancer risk, suggesting differences in microbiome activity along the length of the bowel, say researchers Related items fromOnMedica Cetuximab with chemo shrinks more secondaries Statins might not cut colorectal cancer risk after all Invest in workforce to roll out bowel cancer screening, urges former health secretary Bowel cancer screening tests exceed target set in Scotland FOB associated with rise in all-cause mortality (Source: OnMedica Latest News)
Source: OnMedica Latest News - August 20, 2019 Category: UK Health Source Type: news
